2022
COVID-19 Vaccine Hesitancy among Adolescents: Cross-Sectional School Survey in Four Chinese Cities Prior to Vaccine Availability
Rehati P, Amaerjiang N, Yang L, Xiao H, Li M, Zunong J, Wang L, Vermund SH, Hu Y. COVID-19 Vaccine Hesitancy among Adolescents: Cross-Sectional School Survey in Four Chinese Cities Prior to Vaccine Availability. Vaccines 2022, 10: 452. PMID: 35335083, PMCID: PMC8952375, DOI: 10.3390/vaccines10030452.Peer-Reviewed Original ResearchVaccine hesitancyCOVID-19 vaccine hesitancyLimited health literacyNovel coronavirus disease (COVID-19) pandemicCross-sectional surveyCoronavirus disease (COVID-19) pandemicLow risk awarenessMultivariable analysisMean ageVaccination awarenessVaccination experienceEffective vaccineDoctor's recommendationVaccine preparednessMultinomial logistic regressionVaccine confidenceHealth literacyVaccine availabilityVaccination concernsVaccine resistanceVaccine accessLogistic regressionEmergency useDisease pandemicVaccine
1995
Prevalence of Human Papillomavirus Among STD Clinic Attenders in Jamaica
FIGUEROA J, WARD E, LUTHI T, VERMUND S, BRATHWAITE A, BURK R. Prevalence of Human Papillomavirus Among STD Clinic Attenders in Jamaica. Sexually Transmitted Diseases 1995, 22: 114-118. PMID: 7624812, DOI: 10.1097/00007435-199503000-00007.Peer-Reviewed Original ResearchConceptsHuman papillomavirus infectionHuman papillomavirusPapillomavirus infectionSTD clinicOlder womenHigh HPV prevalenceHuman papillomavirus (HPV) prevalencePrevalence of HPVSTD clinic attendersIncidence of cancerMajor etiologic agentHuman papillomavirus (HPV) genomeLow-stringency Southern blot hybridizationCross-sectional surveyHPV prevalenceEffect of ageClinic attendersCervical cancerWomen 25Risk factorsWomen 20Effective vaccineLow prevalenceWomen 15Etiologic agent
1994
Prevention of HIV/AIDS with vaccines
Vermund S, Schultz A, Hoff R. Prevention of HIV/AIDS with vaccines. Current Opinion In Infectious Diseases 1994, 7: 82-94. DOI: 10.1097/00001432-199402000-00014.Peer-Reviewed Original ResearchHIV vaccineVaccine preparedness studyPhase II trialPhase III trialsHigh-risk populationHuman phase IViral envelope antigensHIV vaccine efficacyHigh behavioral riskLife-long infectionHIV/AIDSRecombinant subunit vaccinesEnvelope vaccinesHIV vaccinationII trialIII trialsClinical updateVaccine efficacyPreventive counselingEffective vaccineEfficacy trialsEnvelope antigenFirst vaccineTrial participantsLive vector